Novo Nordisk has experienced a notable decline in its stock price, dropping by 12.08% over the past week. This downturn comes amid increased competition in the weight loss and dia ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Egg prices in Colorado and around the country remain stubbornly high as a severe bird flu outbreak and ongoing inflation ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Patients who received Lilly’s pill did not show signs of liver damage, the company said. Liver side effects scuttled Pfizer’s ...

The Gila monster is a large, magnificent, and venomous desert-dwelling reptile found throughout the southwestern US and Mexico. A toxic bite from the Gila can cause searing pain, loss of consciousness ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.